Peer-reviewed study demonstrates potent, multi-month extrahepatic delivery via both systemic administration—targeting skeletal muscle, heart, and…
Read More
News & Events
Ractigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy – Nucleic Acids
Ractigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy – Nucleic Acids
Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society
Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society
Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms
